474 related articles for article (PubMed ID: 33203821)
21. Drug Discovery of Small Molecules for the Treatment of COVID-19: A Review on Clinical Studies.
Goel B; Bhardwaj N; Tripathi N; Jain SK
Mini Rev Med Chem; 2021; 21(12):1431-1456. PubMed ID: 33371848
[TBL] [Abstract][Full Text] [Related]
22. Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.
Parums DV
Med Sci Monit; 2022 Jan; 28():e935952. PubMed ID: 34972812
[TBL] [Abstract][Full Text] [Related]
23. Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status.
Banday AH; Shameem SA; Ajaz SJ
SLAS Discov; 2020 Dec; 25(10):1097-1107. PubMed ID: 32692266
[TBL] [Abstract][Full Text] [Related]
24. Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19.
Talluri S
Comb Chem High Throughput Screen; 2021; 24(5):716-728. PubMed ID: 32798373
[TBL] [Abstract][Full Text] [Related]
25. Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an
Mahanta S; Chowdhury P; Gogoi N; Goswami N; Borah D; Kumar R; Chetia D; Borah P; Buragohain AK; Gogoi B
J Biomol Struct Dyn; 2021 Jul; 39(10):3802-3811. PubMed ID: 32406317
[TBL] [Abstract][Full Text] [Related]
26. Recent progress in the repurposing of drugs/molecules for the management of COVID-19.
Sharma D; Kunamneni A
Expert Rev Anti Infect Ther; 2021 Jul; 19(7):889-897. PubMed ID: 33270490
[No Abstract] [Full Text] [Related]
27. Systematic Search for SARS-CoV-2 Main Protease Inhibitors for Drug Repurposing: Ethacrynic Acid as a Potential Drug.
Isgrò C; Sardanelli AM; Palese LL
Viruses; 2021 Jan; 13(1):. PubMed ID: 33451132
[TBL] [Abstract][Full Text] [Related]
28. Drug repurposing for COVID-19 based on an integrative meta-analysis of SARS-CoV-2 induced gene signature in human airway epithelium.
Gupta RK; Nwachuku EL; Zusman BE; Jha RM; Puccio AM
PLoS One; 2021; 16(9):e0257784. PubMed ID: 34582497
[TBL] [Abstract][Full Text] [Related]
29. Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2.
Xiao X; Wang C; Chang D; Wang Y; Dong X; Jiao T; Zhao Z; Ren L; Dela Cruz CS; Sharma L; Lei X; Wang J
Front Immunol; 2020; 11():586572. PubMed ID: 33324406
[TBL] [Abstract][Full Text] [Related]
30. A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2.
Wang S; Sun Q; Xu Y; Pei J; Lai L
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34081143
[TBL] [Abstract][Full Text] [Related]
31. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
32. Identification of SARS-CoV-2 entry inhibitors among already approved drugs.
Yang L; Pei RJ; Li H; Ma XN; Zhou Y; Zhu FH; He PL; Tang W; Zhang YC; Xiong J; Xiao SQ; Tong XK; Zhang B; Zuo JP
Acta Pharmacol Sin; 2021 Aug; 42(8):1347-1353. PubMed ID: 33116249
[TBL] [Abstract][Full Text] [Related]
33. Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data.
Chakraborti S; Bheemireddy S; Srinivasan N
Mol Omics; 2020 Oct; 16(5):474-491. PubMed ID: 32696772
[TBL] [Abstract][Full Text] [Related]
34. Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2.
Biering SB; Van Dis E; Wehri E; Yamashiro LH; Nguyenla X; Dugast-Darzacq C; Graham TGW; Stroumza JR; Golovkine GR; Roberts AW; Fines DM; Spradlin JN; Ward CC; Bajaj T; Dovala D; Schulze-Gamen U; Bajaj R; Fox DM; Ott M; Murthy N; Nomura DK; Schaletzky J; Stanley SA
ACS Infect Dis; 2021 Aug; 7(8):2337-2351. PubMed ID: 34129317
[TBL] [Abstract][Full Text] [Related]
35. Elucidating the Drug Repurposing Spectra of COVID-19 with its Analogues SARS and MERS.
Mishra J; Prasun C; Sahoo PK; Nair MS
Mini Rev Med Chem; 2021; 21(20):3191-3202. PubMed ID: 33632095
[TBL] [Abstract][Full Text] [Related]
36. Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2.
Dittmar M; Lee JS; Whig K; Segrist E; Li M; Kamalia B; Castellana L; Ayyanathan K; Cardenas-Diaz FL; Morrisey EE; Truitt R; Yang W; Jurado K; Samby K; Ramage H; Schultz DC; Cherry S
Cell Rep; 2021 Apr; 35(1):108959. PubMed ID: 33811811
[TBL] [Abstract][Full Text] [Related]
37. Target identification for repurposed drugs active against SARS-CoV-2 via high-throughput inverse docking.
Ribone SR; Paz SA; Abrams CF; Villarreal MA
J Comput Aided Mol Des; 2022 Jan; 36(1):25-37. PubMed ID: 34825285
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro.
Ni Y; Liao J; Qian Z; Wu C; Zhang X; Zhang J; Xie Y; Jiang S
Bioorg Med Chem; 2022 Jan; 53():116523. PubMed ID: 34875467
[TBL] [Abstract][Full Text] [Related]
39. Lessons Learned From Limited Overlap of 15 In Vitro COVID-19 Drug Repurposing Screens.
Tomezsko PJ; Phillipson CW; Walsh ME
Health Secur; 2023; 21(4):249-257. PubMed ID: 37196212
[TBL] [Abstract][Full Text] [Related]
40. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.
Coleman CM; Sisk JM; Mingo RM; Nelson EA; White JM; Frieman MB
J Virol; 2016 Oct; 90(19):8924-33. PubMed ID: 27466418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
